


Neuroanatomical alterations in schizophrenia



This Photo by Unknown Author is licensed under CC BY-SA-NC

© 2018 Otsuka Pharmaceutical Development & Commercialization, Inc., Rockville, MD

Lundbeck, LLC.

December 2018


MRC2.CORP.D.00390


Objectives

- Describe the theoretical course of progression of schizophrenia that leads to functional decline
- Identify the neuroanatomical alterations observed in schizophrenia that may underlie the progressive nature of the disorder
- Describe the neurobiology of relapse and its impact on brain structure




Imaging tools to study progression of SZ







The Theoretical Course of Schizophrenia Progression May Lead to Functional Decline 1-4



High risk of relapse

Lieberman JA, et al. CNS Spectr. 2007;12(10)(suppl 18):1-16;

Negative symptoms

usually develop first,

symptoms

followed by slight positive

- Emsley R, et al. BMC Psychiatry. 2013;13:50;
- McGlashan TH. Schizophr Bull. 1988;14(4):515-542;
 - Lehman AF. Am J Psychiatry. 2004;161(suppl 2):1-56

vary; risk of relapse




other causes

Events may trigger

disease development


Reduced Gray Matter Volume (GMV)

- "Two-hit" hypothesis¹
- Reduction in GM occurs early in disease course²
 - Parietal, motor and temporal cortices
- GM loss progresses with age²
 - Temporal and dorsolateral loss appears later in development (age 18)
- **COMT** variant may impact connectivity in first episode³





Thompson, et al., PNAS, 2001; 98(20): 11650-11655 (Figure)



Copyright (2001) National Academy of Sciences, U.S.A.


Abbreviations: GM: Gray matter; COMT: catechol-o-methyltransferase; STG: superior temporal gyrus; DLPFC: dorsolateral prefrontal cortex; HC: healthy controls; FES: First episode Schizophrenia; RSFC: Resting State Functional Connectivity; ACC: Anterior Cingulate Cortex



Kang, et al., Neuroscience Letters, 2018; epub ahead of print Sep 18 (Figure)

Reduced Gray Matter Volume (GMV)

- "Two-hit" hypothesis¹
- Reduction in GM occurs early in disease course²
 - Parietal, motor and temporal cortices
- GM loss progresses with age²
 - Temporal and dorsolateral loss appears later in development (age 18)
- COMT variant may impact connectivity in first episode³



Copyright (2001) National Academy of Sciences, U.S.A.

Abbreviations: GM: Gray matter; COMT: catechol-o-methyltransferase; STG: superior temporal gyrus; DLPFC: dorsolateral prefrontal cortex; HC: healthy controls; FES: First episode Schizophrenia; RSFC: Resting State Functional Connectivity; ACC: Anterior Cingulate Cortex




^{1.} Koutselaris, et al, Schizophrenia Bulletin, 2014; 40(5): 1140-1153

^{2.} Thompson, et al, PNAS, 2001; 98(20): 11650-11655 (Figure)

^{3.} Kang, et al., Neuroscience Letters, 2018; epub ahead of print Sep 18 (Figure)

Reduced Gray Matter Volume (GMV)

- "Two-hit" hypothesis¹
- Reduction in GM occurs early in disease course²
 - Parietal, motor and temporal cortices
- GM loss progresses with age²
 - Temporal and dorsolateral loss appears later in development (age 18)
- COMT variant may impact connectivity in first episode³



Abbreviations: GM: Gray matter; COMT: catechol-o-methyltransferase; STG: superior temporal gyrus; DLPFC: dorsolateral prefrontal cortex; HC: healthy controls; FES: First episode Schizophrenia; RSFC: Resting State Functional Connectivity; ACC: Anterior Cingulate Cortex




^{1.} Koutselaris, et al., *Schizophrenia Bulletin*, 2014; 40(5): 1140-1153

^{2.} Thompson, et al., PNAS, 2001; 98(20): 11650-11655 (Figure)

^{3.} Kang, et al, Neuroscience Letters, 2018; epub ahead of print Sep 18 (Figure)

Structural changes over lifespan

- Decrease in WM is related to duration of illness¹
 - Glial cell abnormalities
 - Myelination





- Initial, rapid rate of GM loss, slows in middle life²
- Deficit in WM progressively worsens with age at a constant rate²



Cropley, et al, Am J Psychiatry, 2017; 174;286-295

Abbreviations: WM: white matter; GM: gray matter; FA: Fractional Anisotropy








Relapse

Observations from the literature¹

- 1. Relapse rates after treatment discontinuation are very high
- 2. Longer treatment period prior to discontinuation does not reduce risk
- 3. Many patients relapse very soon after discontinuation
- 4. The transition from remission to relapse may be abrupt
- 5. Severity rapidly returns
- Response time is variable and treatment failure may emerge in some



This Photo by Unknown Author is licensed under CC BY-SA




^{1.} Emsley, et al, BMC Psychiatry, 2013;13:50

^{2.} Image: Kane and Correll, *Dialogues Clin Neurosci*; 2010; 12: 345-357

- I. Neuroleptic-induced supersensitivity
- II. Rapid onset psychosis
- **III. Neurotoxicity**
- IV. Dopamine/Glutamate hypotheses
- V. Neuronal sensitization/"kindling"
- VI. Inflammation
 - 1. Emsley, et al *BMC Psychiatry*, 2013;13:50

Mesolimbic Pathway^{2,3}



The mechanism of action of antipsychotics in the treatment of schizophrenia is unknown.

- Stahl SM. Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. 4th Edition. New York, NY: Cambridge University Press; 2013
- 3. Lieberman JA. CNS Drugs. 2004;18(4):251-267.



- I. Neuroleptic-induced supersensitivity
- II. Rapid onset psychosis
- **III. Neurotoxicity**
- IV. Dopamine/Glutamate hypotheses
- V. Neuronal sensitization/"kindling"

Hyperdopaminergia Positive Symptoms Excessive Activity

VI. Inflammation


1. Emsley, et al *BMC Psychiatry*, 2013; 13:50

Adapted from:

- 4. Inoue and Naketa. Jpn J Pharmacol. 2001;86:376.
- Kane et al. J Clin Psychiatry. 2002;63:763.
- 6. Gründer et al. Arch Gen Psychiatry. 2003 60: 974.



- I. Neuroleptic-induced supersensitivity
- II. Rapid onset psychosis
- **III. Neurotoxicity**
- IV. Dopamine/Glutamate hypotheses
- V. Neuronal sensitization/"kindling"



Synaptic plasticity: ongoing, adaptable structural changes involving glutamate receptors and underlying learning, memory, and cognitive changes⁷⁻⁹

VI. Inflammation

1. Emsley, et al BMC Psychiatry 2013; 13:50




Purves D et al (eds). Neuroscience. 2nd Edition. Sinauer Associates, 2001

^{8.} Bermúdez Rattoni F (Ed). Neural Plasticity and Memory: From Genes to Brain Imaging. Boca Raton (FL): CRC Press; 2007

^{9.} Lesch & Waider. Neuron. 2012;76(1):175-191

- I. Neuroleptic-induced supersensitivity
- II. Rapid onset psychosis
- **III. Neurotoxicity**
- IV. Dopamine/Glutamate hypotheses
- V. Neuronal sensitization/"kindling"
- VI. Inflammation




. Emsley, et al BMC Psychiatry. 2013;13:50

10. Image: Miller AH et al. Biol Psychiatry. 2009;65(9):732-741.



Structural changes: Relapse

- Illness Progression follows relapse¹
- "Relapse signature"²
- Duration of relapse, not number of relapses is related to White Matter loss in cortical regions³



- 1. Emsley, et al, Schizophrenia Research, 2013: 148; 117-121
- Cropley and Pantelis, Epidemiology and Psychiatric Sciences, 2014; 23: 219-225
- 3. Andreasen et al, Am J Psych, 2013; 170:609-615




Structural changes: Relapse

- Illness Progression follows relapse¹
- "Relapse signature"²
- Duration of relapse, rather than number of relapses is related to White Matter loss in cortical regions³



^{2.} Cropley and Pantelis, Epidemiology and Psychiatric Sciences, 2014; 23: 219-225






^{3.} Andreasen et al, Am J Psych, 2013; 170:609-615

Effects of Antipsychotics on brain structure

- GM deficit in temporal lobe is specific to schizophrenia and not medication¹
- Overall GMV decrease is associated with higher exposure to antipsychotics and is in line with enlargement of lateral ventricles²
- First episode studies
 - Edinburgh High Risk Study of Schizophrenia: Changes in volume correlated with symptom severity, not medication³
 - WM changes related to pathophysiology of schizophrenia⁴



Copyright (2001) National Academy of Sciences, U.S.A.



Thompson et al, PNAS, 2001:98(20): 11650-11655

Fusar-Poli et al, Neuroscience and Biobehavioral Reviews, 2013; 37:1680-1691

Lawrie, Ther Adv Psychopharmacol, 2018; 8(11): 319-326.

Holleran, et al, *Neuropsychopharm*, 2014; 39: 944-954

Abbreviations: GM: Grav Matter: GMV: Grav Matter Volume: WM: White Matter

Summary

- The progression of schizophrenia that leads to functional decline begins in late adolescence and is accompanied by changes in brain structure and connectivity that contribute to symptom severity and worsening of outcomes.
- Relapse is a complex but common aspect of the disorder and results in further perturbations of brain structure and less favorable outcomes for patients.
- While antipsychotics reduce the likelihood of relapse and may offer some protection against structural alterations associated with schizophrenia, at higher doses they may contribute to these structural changes.





For more information or to request a more detailed live presentation on this topic from your local Medical Science Liaison, please visit www.PsychU.org/events



www.psychu.org